speb/financial-data huggingface dataset:
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 1067000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 4250000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 660000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 29000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 1451000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 275000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 8274000.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 17309000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 5669000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 283952000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 75656000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 170604000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 170604000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 275860000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 275860000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 16292398.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 16323077.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Basic EPS: 1.71
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 0.13
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 2553000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -2005000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 638000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 638000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 33264000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 33264000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -6583000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -2969000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 4837000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Payable: -139274000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 107290000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -36699000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 30711000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 215643000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 262869000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 66382000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 358626000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 358626000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 30200000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 30200000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 30200000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 30200000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 206893000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 206893000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 4071000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 4071000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Depreciation: 2720000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 2720000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 2720000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 741000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 2720000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 741000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 16292398.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 16323077.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Diluted EPS: 1.71
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — EBIT: 34597000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — EBIT: 4690000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — EBITDA: 37317000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 5431000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 33264000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 25386000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -8054000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 6087000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2549000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Gross Profit: 21083000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 9274000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Interest Expense: 101000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 2000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 101000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -101000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 9000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Inventory: 39997000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 39997000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 245843000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 245843000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 11374000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Net Debt: 29562000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 29562000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income Discontinuous Operations: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income Extraordinary: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income Extraordinary: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2122000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 34496000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2122000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Interest Income: -101000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -2000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 25487000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 25487000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -101000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -2000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -9000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 69350000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 69350000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: 11374000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 215643000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 5945000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 5945000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 503000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 503000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 37317000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 5431000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Normalized Income: 27860000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 2122000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: -6049000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Operating Income: 3774000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 3605000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 283952000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 75656000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 16273800.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 16273800.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 189000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 189000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 52905000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 52905000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 101000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 30823000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 1085000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Other Payable: 2018000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 2018000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 32626000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 32626000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Payables: 172622000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 172622000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Pension And Employee Benefit Expense: -31000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 9316000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 9316000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Pretax Income: 34496000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 4688000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -2005000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 262869000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 66382000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 2720000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 741000.00
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 13379000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 504000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 179000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 6591000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2728000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 16273800.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 215643000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 215643000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Tax Provision: 6636000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 2566000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.19
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
BIOFILCHEM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -6636000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 428481000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 428481000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 215643000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 30200000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 30200000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 215643000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 215643000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Total Expenses: 280178000.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 72051000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 212838000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 212838000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 69853000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 69853000.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 5945000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 5945000.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BIOFILCHEM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 151733000.00
BIOFILCHEM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 151733000.00
BIOG.L income_statement (annual, 2022-03-31) — +Operating Expense: -7441000.00
BIOG.L income_statement (annual, 2022-03-31) — +Total Revenue: -209711000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Accounts Payable: 452000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 93092000.00
BIOG.L income_statement (annual, 2022-03-31) — Basic Average Shares: 41441570.00
BIOG.L income_statement (annual, 2022-03-31) — Basic EPS: -4.89
BIOG.L cash_flow (annual, 2022-03-31) — Beginning Cash Position: 1502000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Capital Stock: 10289000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 0.00
BIOG.L balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Federal Funds Sold: 0.00
BIOG.L cash_flow (annual, 2022-03-31) — Cash Dividends Paid: 0.00
BIOG.L cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 0.00
BIOG.L cash_flow (annual, 2022-03-31) — Change In Payable: -18255000.00
BIOG.L cash_flow (annual, 2022-03-31) — Change In Receivables: -14000.00
BIOG.L cash_flow (annual, 2022-03-31) — Change In Working Capital: -18269000.00
BIOG.L cash_flow (annual, 2022-03-31) — Changes In Cash: -1502000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Common Stock: 10289000.00
BIOG.L cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: 0.00
BIOG.L balance_sheet (annual, 2022-03-31) — Common Stock Equity: 394208000.00
BIOG.L cash_flow (annual, 2022-03-31) — Common Stock Issuance: 2097000.00
BIOG.L cash_flow (annual, 2022-03-31) — Common Stock Payments: -6933000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Derivative Product Liabilities: 0.00
BIOG.L income_statement (annual, 2022-03-31) — Diluted Average Shares: 41441570.00
BIOG.L income_statement (annual, 2022-03-31) — Diluted EPS: -4.89
BIOG.L income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: -202419000.00
BIOG.L cash_flow (annual, 2022-03-31) — End Cash Position: 0.00
BIOG.L balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 427399000.00
BIOG.L cash_flow (annual, 2022-03-31) — Financing Cash Flow: -2393000.00
BIOG.L cash_flow (annual, 2022-03-31) — Free Cash Flow: -12141000.00
BIOG.L cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: 204987000.00
BIOG.L income_statement (annual, 2022-03-31) — Gain On Sale Of Security: -204970000.00
BIOG.L income_statement (annual, 2022-03-31) — General And Administrative Expense: 3218000.00
BIOG.L income_statement (annual, 2022-03-31) — Interest Expense: 175000.00
BIOG.L income_statement (annual, 2022-03-31) — Interest Income: 3000.00
BIOG.L cash_flow (annual, 2022-03-31) — Interest Paid Cff: -175000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Invested Capital: 425949000.00
BIOG.L cash_flow (annual, 2022-03-31) — Investing Cash Flow: 13032000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 427399000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Investments And Advances: 427399000.00
BIOG.L cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 2097000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 31741000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: -4836000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Net Debt: 31741000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: 2340000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income: -202419000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income Common Stockholders: -202419000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income Continuous Operations: -202419000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: -202419000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: -202419000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: -202270000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: -202419000.00
BIOG.L income_statement (annual, 2022-03-31) — Net Interest Income: -172000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: 14077000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: 2622000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: 2622000.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Other Financing Charges: 0.00
BIOG.L cash_flow (annual, 2022-03-31) — Net Other Investing Changes: -1045000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 394208000.00
BIOG.L income_statement (annual, 2022-03-31) — Normalized Income: -202419000.00
BIOG.L cash_flow (annual, 2022-03-31) — Operating Cash Flow: -12141000.00
BIOG.L income_statement (annual, 2022-03-31) — Operating Revenue: -209711000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 41158682.00
BIOG.L cash_flow (annual, 2022-03-31) — Other Non Cash Items: 1220000.00
BIOG.L income_statement (annual, 2022-03-31) — Other Operating Expenses: -10729000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Other Payable: 1047000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Payables: 1499000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Prepaid Assets: 49000.00
BIOG.L income_statement (annual, 2022-03-31) — Pretax Income: -202270000.00
BIOG.L cash_flow (annual, 2022-03-31) — Purchase Of Investment: -439160000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Receivables: 0.00
BIOG.L cash_flow (annual, 2022-03-31) — Repurchase Of Capital Stock: -6933000.00
BIOG.L cash_flow (annual, 2022-03-31) — Sale Of Investment: 453237000.00
BIOG.L income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 70000.00
BIOG.L income_statement (annual, 2022-03-31) — Selling General And Administration: 3288000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Share Issued: 41158682.00
BIOG.L balance_sheet (annual, 2022-03-31) — Stockholders Equity: 394208000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Tangible Book Value: 394208000.00
BIOG.L income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: 0.00
BIOG.L income_statement (annual, 2022-03-31) — Tax Provision: 149000.00
BIOG.L income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.19
BIOG.L cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -149000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Total Assets: 427448000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Total Capitalization: 425949000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Total Debt: 31741000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 394208000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 33240000.00
BIOG.L balance_sheet (annual, 2022-03-31) — Treasury Shares Number: 0.00
BIOG.L income_statement (annual, 2023-03-31) — +Operating Expense: 3588000.00
BIOG.L income_statement (annual, 2023-03-31) — +Total Revenue: -37654000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Accounts Payable: 6206000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 93697000.00
BIOG.L income_statement (annual, 2023-03-31) — Basic Average Shares: 40287724.00
BIOG.L income_statement (annual, 2023-03-31) — Basic EPS: -1.03
BIOG.L cash_flow (annual, 2023-03-31) — Beginning Cash Position: 0.00
BIOG.L balance_sheet (annual, 2023-03-31) — Capital Stock: 9684000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 2772000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Federal Funds Sold: 2772000.00
BIOG.L cash_flow (annual, 2023-03-31) — Cash Dividends Paid: 0.00
BIOG.L cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 0.00
BIOG.L cash_flow (annual, 2023-03-31) — Change In Payable: -116000.00
BIOG.L cash_flow (annual, 2023-03-31) — Change In Receivables: 28000.00
BIOG.L cash_flow (annual, 2023-03-31) — Change In Working Capital: -88000.00
BIOG.L cash_flow (annual, 2023-03-31) — Changes In Cash: 2772000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Common Stock: 9684000.00
BIOG.L cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: 0.00
BIOG.L balance_sheet (annual, 2023-03-31) — Common Stock Equity: 330291000.00
BIOG.L cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
BIOG.L cash_flow (annual, 2023-03-31) — Common Stock Payments: -20910000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Derivative Product Liabilities: 1202000.00
BIOG.L income_statement (annual, 2023-03-31) — Diluted Average Shares: 40287724.00
BIOG.L income_statement (annual, 2023-03-31) — Diluted EPS: -1.03
BIOG.L income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: -41298000.00
BIOG.L cash_flow (annual, 2023-03-31) — End Cash Position: 2772000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 357229000.00
BIOG.L cash_flow (annual, 2023-03-31) — Financing Cash Flow: -37032000.00
BIOG.L cash_flow (annual, 2023-03-31) — Free Cash Flow: -5890000.00
BIOG.L cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: 30945000.00
BIOG.L income_statement (annual, 2023-03-31) — Gain On Sale Of Security: -30929000.00
BIOG.L income_statement (annual, 2023-03-31) — General And Administrative Expense: 3520000.00
BIOG.L income_statement (annual, 2023-03-31) — Interest Expense: 792000.00
BIOG.L income_statement (annual, 2023-03-31) — Interest Income: 11000.00
BIOG.L cash_flow (annual, 2023-03-31) — Interest Paid Cff: -792000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Invested Capital: 350461000.00
BIOG.L cash_flow (annual, 2023-03-31) — Investing Cash Flow: 45694000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 357229000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Investments And Advances: 357229000.00
BIOG.L cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
BIOG.L balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 20170000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -20910000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Net Debt: 17398000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 3759000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income: -41298000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -41298000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -41298000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -41298000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -41298000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: -41242000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -41298000.00
BIOG.L income_statement (annual, 2023-03-31) — Net Interest Income: -781000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 45694000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -15330000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -15330000.00
BIOG.L cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 0.00
BIOG.L balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 330291000.00
BIOG.L income_statement (annual, 2023-03-31) — Normalized Income: -41298000.00
BIOG.L cash_flow (annual, 2023-03-31) — Operating Cash Flow: -5890000.00
BIOG.L income_statement (annual, 2023-03-31) — Operating Revenue: -37654000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 38737419.00
BIOG.L cash_flow (annual, 2023-03-31) — Other Non Cash Items: 792000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Other Payable: 2640000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Payables: 8846000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Prepaid Assets: 21000.00
BIOG.L income_statement (annual, 2023-03-31) — Pretax Income: -41242000.00
BIOG.L cash_flow (annual, 2023-03-31) — Purchase Of Investment: -459606000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Receivables: 487000.00
BIOG.L cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -20910000.00
BIOG.L cash_flow (annual, 2023-03-31) — Sale Of Investment: 505300000.00
BIOG.L income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 68000.00
BIOG.L income_statement (annual, 2023-03-31) — Selling General And Administration: 3588000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Share Issued: 38737419.00
BIOG.L balance_sheet (annual, 2023-03-31) — Stockholders Equity: 330291000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Tangible Book Value: 330291000.00
BIOG.L income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 0.00
BIOG.L income_statement (annual, 2023-03-31) — Tax Provision: 56000.00
BIOG.L income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.19
BIOG.L cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -56000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Total Assets: 360509000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Total Capitalization: 350461000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Total Debt: 20170000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 330291000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 30218000.00
BIOG.L balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 0.00
BIOG.L income_statement (annual, 2024-03-31) — +Operating Expense: 3240000.00
BIOG.L income_statement (annual, 2024-03-31) — +Total Revenue: 77999000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Accounts Payable: 167000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 95010000.00
BIOG.L income_statement (annual, 2024-03-31) — Basic Average Shares: 36041496.00
BIOG.L income_statement (annual, 2024-03-31) — Basic EPS: 2.07
BIOG.L cash_flow (annual, 2024-03-31) — Beginning Cash Position: 2772000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Capital Stock: 8371000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 2131000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Federal Funds Sold: 2131000.00
BIOG.L cash_flow (annual, 2024-03-31) — Cash Dividends Paid: 0.00
BIOG.L cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 0.00
BIOG.L cash_flow (annual, 2024-03-31) — Change In Payable: 98000.00
BIOG.L cash_flow (annual, 2024-03-31) — Change In Receivables: -6000.00
BIOG.L cash_flow (annual, 2024-03-31) — Change In Working Capital: 92000.00
BIOG.L cash_flow (annual, 2024-03-31) — Changes In Cash: -641000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Common Stock: 8371000.00
BIOG.L cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: 0.00
BIOG.L balance_sheet (annual, 2024-03-31) — Common Stock Equity: 361307000.00
BIOG.L cash_flow (annual, 2024-03-31) — Common Stock Payments: -43913000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 460000.00
BIOG.L income_statement (annual, 2024-03-31) — Diluted Average Shares: 36041496.00
BIOG.L income_statement (annual, 2024-03-31) — Diluted EPS: 2.07
BIOG.L income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 74600000.00
BIOG.L cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 0.00
BIOG.L cash_flow (annual, 2024-03-31) — End Cash Position: 2131000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 394712000.00
BIOG.L cash_flow (annual, 2024-03-31) — Financing Cash Flow: -18741000.00
BIOG.L cash_flow (annual, 2024-03-31) — Free Cash Flow: -4241000.00
BIOG.L cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -80669000.00
BIOG.L income_statement (annual, 2024-03-31) — Gain On Sale Of Security: 80669000.00
BIOG.L income_statement (annual, 2024-03-31) — General And Administrative Expense: 3169000.00
BIOG.L income_statement (annual, 2024-03-31) — Interest Expense: 1115000.00
BIOG.L income_statement (annual, 2024-03-31) — Interest Income: 123000.00
BIOG.L cash_flow (annual, 2024-03-31) — Interest Paid Cff: -1115000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Invested Capital: 408385000.00
BIOG.L cash_flow (annual, 2024-03-31) — Investing Cash Flow: 22341000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 394754000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Investments And Advances: 394754000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 47078000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -43913000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Net Debt: 44947000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 621000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income: 74600000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 74600000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 74600000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 74600000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 74600000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 74759000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 74600000.00
BIOG.L income_statement (annual, 2024-03-31) — Net Interest Income: -992000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 22341000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 26287000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 26287000.00
BIOG.L cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 0.00
BIOG.L balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 361307000.00
BIOG.L income_statement (annual, 2024-03-31) — Normalized Income: 74600000.00
BIOG.L cash_flow (annual, 2024-03-31) — Operating Cash Flow: -4241000.00
BIOG.L income_statement (annual, 2024-03-31) — Operating Revenue: 77999000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 33487198.00
BIOG.L cash_flow (annual, 2024-03-31) — Other Non Cash Items: 1115000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Other Payable: 2408000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Payables: 2575000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Prepaid Assets: 27000.00
BIOG.L income_statement (annual, 2024-03-31) — Pretax Income: 74759000.00
BIOG.L cash_flow (annual, 2024-03-31) — Purchase Of Investment: -350835000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Receivables: 14508000.00
BIOG.L cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -43913000.00
BIOG.L cash_flow (annual, 2024-03-31) — Sale Of Investment: 373176000.00
BIOG.L income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 71000.00
BIOG.L income_statement (annual, 2024-03-31) — Selling General And Administration: 3240000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Share Issued: 33487198.00
BIOG.L balance_sheet (annual, 2024-03-31) — Stockholders Equity: 361307000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Tangible Book Value: 361307000.00
BIOG.L income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 0.00
BIOG.L income_statement (annual, 2024-03-31) — Tax Provision: 159000.00
BIOG.L income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.00
BIOG.L cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -159000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Total Assets: 411420000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Total Capitalization: 408385000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Total Debt: 47078000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 361307000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 50113000.00
BIOG.L balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Additional Paid In Capital: 95390000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Capital Stock: 7991000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 3968000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Federal Funds Sold: 3968000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Common Stock: 7991000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 354116000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Derivative Product Liabilities: 130000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 375256000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Invested Capital: 393140000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 375507000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Investments And Advances: 375507000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 39024000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Net Debt: 35056000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 354116000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 31963979.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Other Payable: 13172000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Payables: 13172000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Receivables: 26967000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Share Issued: 31963979.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 354116000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 354116000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Total Assets: 406442000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 393140000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Total Debt: 39024000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 354116000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 52326000.00
BIOG.L balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 0.00
BIOG.L income_statement (annual, 2025-03-31) — +Operating Expense: 3707000.00
BIOG.L income_statement (annual, 2025-03-31) — +Total Revenue: -78809000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Accounts Payable: 405000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 405000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 96603000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 96603000.00
BIOG.L income_statement (annual, 2025-03-31) — Basic Average Shares: 31514115.00
BIOG.L income_statement (annual, 2025-03-31) — Basic EPS: -2.62
BIOG.L cash_flow (annual, 2025-03-31) — Beginning Cash Position: 2131000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Capital Stock: 6778000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Capital Stock: 6778000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 8453000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 8453000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Federal Funds Sold: 8453000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Federal Funds Sold: 8453000.00
BIOG.L cash_flow (annual, 2025-03-31) — Cash Dividends Paid: 0.00
BIOG.L balance_sheet (annual, 2025-03-31) — Cash Equivalents: 6913000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 6913000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Cash Financial: 1540000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Cash Financial: 1540000.00
BIOG.L cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 0.00
BIOG.L cash_flow (annual, 2025-03-31) — Change In Payable: -347000.00
BIOG.L cash_flow (annual, 2025-03-31) — Change In Receivables: 10000.00
BIOG.L cash_flow (annual, 2025-03-31) — Change In Working Capital: -337000.00
BIOG.L cash_flow (annual, 2025-03-31) — Changes In Cash: 6469000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Common Stock: 6778000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Common Stock: 6778000.00
BIOG.L cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: 0.00
BIOG.L balance_sheet (annual, 2025-03-31) — Common Stock Equity: 221206000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 221206000.00
BIOG.L cash_flow (annual, 2025-03-31) — Common Stock Payments: -54483000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Derivative Product Liabilities: 0.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 0.00
BIOG.L income_statement (annual, 2025-03-31) — Diluted Average Shares: 31514115.00
BIOG.L income_statement (annual, 2025-03-31) — Diluted EPS: -2.62
BIOG.L income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: -82661000.00
BIOG.L cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -147000.00
BIOG.L cash_flow (annual, 2025-03-31) — End Cash Position: 8453000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 217414000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 217414000.00
BIOG.L cash_flow (annual, 2025-03-31) — Financing Cash Flow: -104292000.00
BIOG.L cash_flow (annual, 2025-03-31) — Free Cash Flow: -5087000.00
BIOG.L cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: 75033000.00
BIOG.L income_statement (annual, 2025-03-31) — Gain On Sale Of Security: -75033000.00
BIOG.L income_statement (annual, 2025-03-31) — General And Administrative Expense: 3621000.00
BIOG.L income_statement (annual, 2025-03-31) — Interest Expense: 1325000.00
BIOG.L income_statement (annual, 2025-03-31) — Interest Income: 147000.00
BIOG.L cash_flow (annual, 2025-03-31) — Interest Paid Cff: -1325000.00
BIOG.L cash_flow (annual, 2025-03-31) — Investing Cash Flow: 115848000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 218159000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 218159000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Investments And Advances: 218159000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 218159000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -54483000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 1553000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income: -82661000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income Common Stockholders: -82661000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income Continuous Operations: -82661000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -82661000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -82661000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: -82516000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: -82661000.00
BIOG.L income_statement (annual, 2025-03-31) — Net Interest Income: -1178000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 115848000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -48484000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -48484000.00
BIOG.L cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 0.00
BIOG.L balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 221206000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 221206000.00
BIOG.L income_statement (annual, 2025-03-31) — Normalized Income: -82661000.00
BIOG.L cash_flow (annual, 2025-03-31) — Operating Cash Flow: -5087000.00
BIOG.L income_statement (annual, 2025-03-31) — Operating Revenue: -78809000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 27112591.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 27112591.00
BIOG.L cash_flow (annual, 2025-03-31) — Other Non Cash Items: 1325000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Other Payable: 5018000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Other Payable: 5018000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Payables: 5423000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Payables: 5423000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Prepaid Assets: 17000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 17000.00
BIOG.L income_statement (annual, 2025-03-31) — Pretax Income: -82516000.00
BIOG.L cash_flow (annual, 2025-03-31) — Purchase Of Investment: -429202000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Receivables: 0.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Receivables: 0.00
BIOG.L cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -54483000.00
BIOG.L cash_flow (annual, 2025-03-31) — Sale Of Investment: 545050000.00
BIOG.L income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 86000.00
BIOG.L income_statement (annual, 2025-03-31) — Selling General And Administration: 3707000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Share Issued: 27112591.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Share Issued: 27112591.00
BIOG.L balance_sheet (annual, 2025-03-31) — Stockholders Equity: 221206000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 221206000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Tangible Book Value: 221206000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 221206000.00
BIOG.L income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
BIOG.L income_statement (annual, 2025-03-31) — Tax Provision: 145000.00
BIOG.L income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.25
BIOG.L cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -145000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Total Assets: 226629000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Total Assets: 226629000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 221206000.00
BIOG.L balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 221206000.00
BIOG.L balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 5423000.00